

G(5')ppp(5')A RNA Cap Structure Analog



1-800-632-7799
info@neb.com
www.neb.com



S1406S 001170120011

S1406S

1 μ mol Lot: 0011701
Store at -20°C Exp: 1/20

G(5')ppp(5')A Sodium Salt

Description: The 5' terminal m⁷G cap present on most eukaryotic mRNAs promotes translation *in vitro* at the initiation level (1,2,3). For most RNAs, elimination of the cap structure causes a loss of stability, especially against exonuclease degradation (4), and a decrease in the formation of the initiation complex of mRNAs for protein synthesis (4,5). Certain prokaryotic mRNAs containing a 5'

terminal cap structure are translated as efficiently as or more efficiently than eukaryotic mRNAs in a eukaryotic cell-free protein synthesizing system (5). Also a cap requirement has been observed for splicing eukaryotic substrate RNAs (6).

A method using *E. coli* RNA polymerase primed with m⁷G(5')ppp(5')G or m⁷G(5')ppp(5')A for an efficient *in vitro* synthesis of capped RNAs has been developed by Contreas (7). Larger amounts of capped RNAs are produced by transcription systems using SP6 RNA polymerase primed with m⁷G(5')ppp(5')G (6).

Quality Controls

The purity and identity of G(5')ppp(5')A (Cap Analog) is $\geq 95\%$ as determined by HPLC analysis and mass spec respectively.

The RNA Cap Structure Analog is functionally tested for recognition by an RNA Polymerase and its incorporation into a run-off transcript.

G(5')ppp(5')A RNA Cap Structure Analog



1-800-632-7799
info@neb.com
www.neb.com



S1406S 001170120011

S1406S

1 μ mol Lot: 0011701
Store at -20°C Exp: 1/20

G(5')ppp(5')A Sodium Salt

Description: The 5' terminal m⁷G cap present on most eukaryotic mRNAs promotes translation *in vitro* at the initiation level (1,2,3). For most RNAs, elimination of the cap structure causes a loss of stability, especially against exonuclease degradation (4), and a decrease in the formation of the initiation complex of mRNAs for protein synthesis (4,5). Certain prokaryotic mRNAs containing a 5'

terminal cap structure are translated as efficiently as or more efficiently than eukaryotic mRNAs in a eukaryotic cell-free protein synthesizing system (5). Also a cap requirement has been observed for splicing eukaryotic substrate RNAs (6).

A method using *E. coli* RNA polymerase primed with m⁷G(5')ppp(5')G or m⁷G(5')ppp(5')A for an efficient *in vitro* synthesis of capped RNAs has been developed by Contreas (7). Larger amounts of capped RNAs are produced by transcription systems using SP6 RNA polymerase primed with m⁷G(5')ppp(5')G (6).

Quality Controls

The purity and identity of G(5')ppp(5')A (Cap Analog) is $\geq 95\%$ as determined by HPLC analysis and mass spec respectively.

The RNA Cap Structure Analog is functionally tested for recognition by an RNA Polymerase and its incorporation into a run-off transcript.

Molecular Formula: C₂₀H₂₇N₁₀O₁₇P₃ (Free Acid)

Molecular Weight: 772.41 g/mol (Free acid)

Extinction Coefficient: $\lambda_{260} = \sim 27,100 \text{ Lmol}^{-1} \text{ cm}^{-1}$

Note: Addition of 100 μ l water gives approximately a 10 mM solution.

References:

1. Shatkin, A.J. (1978) *Cell*. 9, 645–653.
2. Fillipowicz, W. (1978) *FEBS Lett* 96, 1–11.
3. Banerjee, A.K. (1980) *Microbiol. Rev.* 44, 175–205.
4. Miura, K. (1981) *Adv. Biophys.* 14, 205–238.
5. Shatkin, A.J. et al. (1977) *Nucleic Acids. Res.* 4, 3065–3081.
6. Konarska, M.M. et al. (18984) *Cell* 38, 731–736.
7. Contreas, R. et al. (1982) *Nucleic Acids. Res.* 10, 6353–6363.
8. Paterson, B.M. and Rosenberg, M. (1979) *Nature* 279, 696–701.

Molecular Formula: C₂₀H₂₇N₁₀O₁₇P₃ (Free Acid)

Molecular Weight: 772.41 g/mol (Free acid)

Extinction Coefficient: $\lambda_{260} = \sim 27,100 \text{ Lmol}^{-1} \text{ cm}^{-1}$

Note: Addition of 100 μ l water gives approximately a 10 mM solution.

References:

1. Shatkin, A.J. (1978) *Cell*. 9, 645–653.
2. Fillipowicz, W. (1978) *FEBS Lett* 96, 1–11.
3. Banerjee, A.K. (1980) *Microbiol. Rev.* 44, 175–205.
4. Miura, K. (1981) *Adv. Biophys.* 14, 205–238.
5. Shatkin, A.J. et al. (1977) *Nucleic Acids. Res.* 4, 3065–3081.
6. Konarska, M.M. et al. (18984) *Cell* 38, 731–736.
7. Contreas, R. et al. (1982) *Nucleic Acids. Res.* 10, 6353–6363.
8. Paterson, B.M. and Rosenberg, M. (1979) *Nature* 279, 696–701.



NEW ENGLAND BIOLABS® is a registered trademark of New England Biolabs, Inc.

This product is intended for research purposes only. This product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

CERTIFICATE OF ANALYSIS



NEW ENGLAND BIOLABS® is a registered trademark of New England Biolabs, Inc.

This product is intended for research purposes only. This product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

CERTIFICATE OF ANALYSIS